Published in Nature on November 19, 2008
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol (2012) 3.32
DNA damage-mediated induction of a chemoresistant niche. Cell (2010) 2.94
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell (2010) 2.43
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology (2010) 2.31
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med (2010) 2.17
IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 2.14
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet (2015) 1.86
Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81
Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med (2011) 1.78
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci (2011) 1.70
A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature (2015) 1.56
Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol (2009) 1.55
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res (2012) 1.43
MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One (2013) 1.28
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26
A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest (2011) 1.25
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2010) 1.25
Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest (2012) 1.24
β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. Gastroenterology (2015) 1.20
Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet (2010) 1.16
Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int (2011) 1.14
Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes (2010) 1.13
SOCS, inflammation, and cancer. JAKSTAT (2013) 1.13
The two faces of IL-6 in the tumor microenvironment. Semin Immunol (2014) 1.10
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol (2012) 1.04
STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer (2011) 1.04
mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest (2013) 1.03
Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene (2015) 1.03
Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell (2015) 1.02
A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors. Dis Model Mech (2012) 1.00
Chemotherapeutic resistance: surviving stressful situations. Cancer Res (2011) 0.99
Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer (2010) 0.97
Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One (2013) 0.95
Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell (2010) 0.93
Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem (2012) 0.91
The Wnt/β-catenin signaling pathway in liver biology and disease. Expert Rev Gastroenterol Hepatol (2010) 0.90
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
A four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases. Front Immunol (2011) 0.89
HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. BMC Cancer (2011) 0.87
A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol (2012) 0.87
Molecular pathogenesis of hepatic adenomas and its implications for surgical management. J Gastrointest Surg (2013) 0.86
Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget (2014) 0.85
Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Oncoimmunology (2012) 0.85
Cell-specific RNA interference by peptide-inhibited-peptidase-activated siRNAs. J RNAi Gene Silencing (2010) 0.85
A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep (2011) 0.85
Determinants of the extent and duration of STAT3 signaling. JAKSTAT (2012) 0.85
Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells. Mol Cell Biol (2014) 0.85
Histological and immunohistochemical revision of hepatocellular adenomas: a learning experience. Int J Hepatol (2013) 0.84
IL-6 mediates the susceptibility of glycoprotein 130 hypermorphs to Toxoplasma gondii. J Immunol (2011) 0.84
Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology (2014) 0.84
SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma. Int J Biol Sci (2014) 0.84
Molecular classification of hepatocellular adenomas. Int J Hepatol (2013) 0.83
Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol (2015) 0.82
HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes. PLoS One (2013) 0.82
Cancer and diet: How are they related? Free Radic Res (2011) 0.81
The Role of STAT3 in Thyroid Cancer. Cancers (Basel) (2014) 0.80
Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome (2014) 0.80
Overview of hepatocellular adenoma in Japan. Int J Hepatol (2012) 0.80
Stat3 is a candidate epigenetic biomarker of perinatal Bisphenol A exposure associated with murine hepatic tumors with implications for human health. Epigenetics (2015) 0.80
Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. Cell Death Dis (2015) 0.79
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors. Future Oncol (2009) 0.79
Inflammation and skeletal metastasis. Bonekey Rep (2015) 0.79
Platelet factor 4 inhibits IL-17/Stat3 pathway via upregulation of SOCS3 expression in melanoma. Inflammation (2014) 0.79
The JAK2-Akt-glycogen synthase kinase-3β signaling pathway is involved in toll-like receptor 2-induced monocyte chemoattractant protein-1 regulation. Mol Med Rep (2012) 0.79
A new link between cancer and inflammation? J Hepatol (2009) 0.78
Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun (2015) 0.78
How normal is the liver in which the inflammatory type hepatocellular adenoma develops? Int J Hepatol (2012) 0.78
Hydroxyflavanone inhibits gastric carcinoma MGC-803 cell proliferation. Int J Clin Exp Med (2015) 0.78
Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care. Cancer Cell (2014) 0.78
Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies. Cell Commun Signal (2014) 0.77
Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol (2013) 0.77
Mycotoxin Patulin Suppresses Innate Immune Responses by Mitochondrial Dysfunction and p62/Sequestosome-1-dependent Mitophagy. J Biol Chem (2016) 0.76
Focal nodular hyperplasia with major sinusoidal dilatation: a misleading entity. BMJ Case Rep (2010) 0.76
Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Mod Pathol (2015) 0.75
SSAT/AHPBA joint symposium on evaluation and treatment of benign liver lesions. J Gastrointest Surg (2013) 0.75
Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther (2016) 0.75
Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. Oncotarget (2016) 0.75
Increasing the Inflammatory Competence of Macrophages with IL-6 or with Combination of IL-4 and LPS Restrains the Invasiveness of Pancreatic Cancer Cells. J Cancer (2016) 0.75
The Role of the Transcriptional Regulation of Stromal Cells in Chronic Inflammation. Biomolecules (2015) 0.75
The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. World J Surg Oncol (2016) 0.75
Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. Diagn Pathol (2016) 0.75
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat Commun (2016) 0.75
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Hepatology (2009) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol (2001) 15.02
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol (2003) 4.90
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Interleukin-6 family of cytokines and gp130. Blood (1995) 4.52
Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med (2002) 4.28
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science (1994) 4.24
Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science (1994) 4.07
The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev (2003) 3.96
Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol (1993) 3.37
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13
Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science (2003) 2.87
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology (2006) 2.13
Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol (2005) 2.12
Structure of an extracellular gp130 cytokine receptor signaling complex. Science (2001) 1.94
Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology (2004) 1.79
High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem (1994) 1.57
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 1.50
HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem (2007) 1.36
Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation. Hepatology (2005) 1.01
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (2009) 2.20
Structural dynamics of alpha-actinin-vinculin interactions. Mol Cell Biol (2005) 2.12
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival. Am J Surg Pathol (2008) 1.98
Mapping the interaction surface of linker histone H1(0) with the nucleosome of native chromatin in vivo. Nat Struct Mol Biol (2006) 1.94
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Deciphering cellular states of innate tumor drug responses. Genome Biol (2006) 1.83
Genetics of hepatobiliary carcinogenesis. Semin Liver Dis (2011) 1.79
Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol (2005) 1.79
Raver1 interactions with vinculin and RNA suggest a feed-forward pathway in directing mRNA to focal adhesions. Structure (2009) 1.77
Crystal structure of human vinculin. Structure (2004) 1.73
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70
Global analysis of extracytoplasmic stress signaling in Escherichia coli. PLoS Genet (2009) 1.69
Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet (2007) 1.68
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A (2005) 1.67
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol (2007) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
The vinculin binding sites of talin and alpha-actinin are sufficient to activate vinculin. J Biol Chem (2006) 1.62
Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. Dev Cell (2004) 1.62
Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology (2008) 1.58
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.48
Hepatocellular adenomas. Liver Int (2008) 1.47
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab (2004) 1.46
Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis (2008) 1.39
The Human Anatomic Gene Expression Library (H-ANGEL), the H-Inv integrative display of human gene expression across disparate technologies and platforms. Nucleic Acids Res (2005) 1.39
Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology (2013) 1.36
HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem (2007) 1.36
Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis (2011) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Subtype classification of hepatocellular adenoma. Dig Surg (2010) 1.33
CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer (2011) 1.26
Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol (2012) 1.25